OMAHA, Neb., Sept. 7, 2011 /PRNewswire/ — Transgenomic, Inc.
(OTC/BB: TBIO) today announced that Craig Tuttle, President and
Chief Executive Officer of Transgenomic, will be presenting at the
Rodman & Renshaw 13th Annual Healthcare Conference on Tuesday,
September 13th at 11:40 AM Eastern Time at the Waldorf=Astoria
Hotel in New York City.
The presentation will be webcast live at http://www.wsw.com/webcast/rrshq20/tbio
and is available for viewing at the Company’s web site at http://www.transgenomic.com/events.asp?id=6
where it will also be archived for 90 days.
Transgenomic, Inc. (www.transgenomic.com) is a
global biotechnology company advancing personalized medicine in
cancer and inherited diseases through its proprietary molecular
technologies and world-class clinical and research services. The
Company has three complementary business divisions: Transgenomic
Pharmacogenomic Services is a contract research laboratory that
specializes in supporting all phases of pre-clinical and clinical
trials for oncology drugs in development. Transgenomic Clinical
Laboratories specializes in molecular diagnostics for cardiology,
neurology, mitochondrial disorders, and oncology. Transgenomic
Diagnostic Tools produces equipment, reagents, and other
consumables that empower clinical and research applications in
molecular testing and cytogenetics. Transgenomic believes there is
significant opportunity for continued growth across all three
businesses by leveraging their synergistic capabilities,
technologies, and expertise. The Company actively develops and
acquires new technology and other intellectual property that
strengthen its leadership in personalized medicine.